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Introduction
Gastric cancer accounted for 951 600 new cancer cases and 723 100 deaths in 2012 [1] . Complete resection is essential to cure localized gastric cancer [2] . At present, the standard treatments of locally advanced gastric cancer in Asia, Europe and the USA are D2 gastrectomy followed by adjuvant chemotherapy, surgery with pre-and postoperative chemotherapy, and surgery with postoperative chemoradiotherapy, respectively [3] [4] [5] [6] . However, even with D2 gastrectomy and adjuvant S-1 chemotherapy, the prognosis for serosa-positive tumors is relatively poor [7] .
Preoperative (neoadjuvant) chemotherapy followed by extended surgery has some theoretical benefits when compared with postoperative chemotherapy [8] . Several Phase II studies have shown that cisplatin and S-1 (CS), a standard regimen administered for metastatic gastric cancer in Japan, was safe, feasible and effective in the neoadjuvant setting [9, 10] . A triplet regimen using docetaxel, cisplatin and S-1 (DCS) also showed relatively a high response rate with acceptable toxicities in two Phase II studies [11, 12] . Docetaxel is a key drug used to treat metastatic gastric cancer [13] . Both CS and DCS are promising regimens for neoadjuvant chemotherapy (NAC); however, a suitable duration of treatment has not yet been established. We previously found that two courses of CS as NAC were effective in a test arm of a future phase III study for patients with locally advanced gastric cancer [14] . However, a suitable duration for the DCS triplet regimen has not yet been established.
On the basis of these previous studies, a randomized phase II trial was conducted to compare NAC using two and four courses of CS and DCS with a two-by-two factorial design for macroscopically resectable locally advanced gastric cancer [15] . The primary endpoint was the overall survival (OS). The present study was a randomized phase II trial intended not to draw definite conclusions but to select a better regimen and course for the next phase III trial. This report clarified the impact of these regimens on early endpoints, including the pathological responses, chemotherapyrelated toxicities and surgical outcomes.
Patients and methods

Eligibility criteria
Tumors are staged according to the 14th edition of the Japanese Gastric Cancer Classification [16] . The eligibility criteria were as follows: (i) histologically proved adenocarcinoma of the stomach; (ii) clinical T4, or T3 disease in cases of tumors invading the esophagus and/or of the scirrhous type, including giant type 3 with a maximum diameter of >8 cm, as confirmed by abdominal computed tomography (CT) and laparoscopy. The T and N stages were determined only by CT, with reference to the method proposed by Habermann et al. [17] . Endoscopic ultrasound (EUS) was not mandatory in this trial because EUS is not routinely carried out in Japan; (iii) no pleural effusion, no ascites exceeding the pelvis and no metastasis to the peritoneum, liver or other distant organs, as confirmed by abdominal-pelvic CT; (iv) no metastasis to the lung, mediastinal lymph nodes or other distant organs, as confirmed by thoracic CT for tumors invading the esophagus; (v) no clinically apparent distant metastasis; (vi) age ranging between 20 and 80 years; (vii) ECOG performance status (PS) 0-1; (viii) sufficient oral intake; (ix) no previous treatment with chemotherapy or radiation therapy for any tumors; and (x) no previous surgery for the present disease except bypass surgery.
The exclusion criteria were as follows: (i) remnant stomach cancer; (ii) synchronous or metachronous cancer (synchronous multiple cancers in the stomach included); (iii) females with an ongoing pregnancy or breastfeeding, or who were contemplating becoming pregnant; (iv) mental disorders that might affect the ability or willingness to provide informed consent or abide by the study protocol; (v) systemic treatment with a corticosteroid; (vi) systemic treatment with flucytosine, phenytoin or warfarin potassium; (vii) allergic reaction to iodine; (viii) hypersensitivity to docetaxel, cisplatin or polysorbate; (ix) peripheral neuropathy; (x) edema; (xi) pneumonitis, lung fibrosis or emphysema in need for oxygen therapy; (xii) active inflammation due to bacteria or fungi; (xiii) unstable angina or cardiac infarction within the previous 6 months; (xiv) positivity for HBs antigen or HCV antibody; (xv) unstable hypertension; and (xvi) diabetes mellitus under treatment.
Preoperative chemotherapy
The patients enrolled in this study received one of the following NAC regimens: 
Surgery and adjuvant chemotherapy
After completing NAC or when the tumors progress during treatment, patients undergo gastrectomy with standard D2 lymphadenectomy [18] . D3 dissection or combined resection of a small part of the peritoneum or adjacent organs is permitted for curative intent, but more invasive surgeries, such as pancreaticoduodenectomy or Appleby's surgery, are not. When achieving curative surgery, S-1 of 80 mg/m 2 p.o. daily for 28 days, every 6 weeks, is initiated within 6 weeks after surgery and continued for 1 year.
Registration
The participating investigators were instructed to send an eligibility criteria report to the Data Center at the nonprofit organization Kanagawa Standard Anti-cancer Therapy Support System. Eligible patients were registered and then randomized to one of the four groups (A, B, C and D) by a centralized dynamic method using the following factors as balancing variables: scirrhous type including giant type 3 (yes/no), tumors invading the esophagus (yes/no), cT3-4a/T4b disease, lymph node metastasis (yes/ no) and institution. Information regarding the necessary follow-up examinations and chemotherapy schedule were then sent from the data center. The accrual was started in October 2011 and continued for 3 years.
The evaluation of the pathological response
In the present study, the pathological response was evaluated using the modified Japanese classification of gastric carcinoma: 3rd English edition [16] . The histological response of the primary tumor was evaluated in the section where the tumor was thought to have been located at the pretreatment assessment and in the sections where tumor cells were likely to remain. Viable tumor cells were defined as cells judged to be capable of proliferation. Surgical specimens were pathologically evaluated as grade 0 when there was no degeneration and/or necrosis within the tumor, grade 1a when the degeneration area was less than one-third of the tumor, grade 1b when the degeneration area was more than one-third and less than two-thirds, grade 2a when the degeneration area was more than two-thirds but <90%, grade 2b when the degeneration area was more than 90% but <100%, and grade 3 when there was no residual tumor. According to the previous studies, we defined the 'pathological response rate' as tumor regression >90%, which corresponded to grade 2b and grade 3 [19] . In the present study, the evaluation of the pathological response was not done centrally, and the exchange of slides/pictures was not carried out between the involved pathologists.
Study design and statistical methods
The present study is a randomized phase II trial of the selection design proposed by Simon et al. [20] . This study was primarily designed to evaluate (i) the effectiveness of four courses of NAC compared with two courses and (ii) the effectiveness of the DCS regimen compared with CS. For each purpose, the regimen showing a higher 3-year OS was considered more promising for a subsequent phase III trial.
Although it is difficult to predict the 3-year survival rate accurately, we initially predicted that the 3-year survival rate would be around 50% in the reference arm of the COMPASS-D trial. The triplet and four-course regimens are more toxic than doublet and two-course ones. As such, considering the balance between the risks and benefits, the other arm of the triplet or four-course regimens was expected to have at least a 10% better 3-year survival rate than the doublet and two-course ones. We therefore assumed that the 3-year OS of one regimen would be 50% and that of the other regimen would be 60% [3] .
The sample size required to ensure 85% probability of the correct selection of a more effective regimen was calculated to be 110 patients, with 55 patients per arm. Considering the likelihood of dropouts and ineligible patients, the number of patients to be accrued was set at 120 in total.
The primary analysis in this study aimed to estimate the 3-year OS. The pathological response, clinical response, R0 resection rate, R0R1 resection rate, completion rate of the treatment and completion rate of NAC were calculated as proportions with exact confidence intervals and then compared with Fisher's exact test.
Results
Patients
Between October 2011 and September 2014, a total of 132 patients were assigned to arm A (2 courses of CS, n ¼33), arm B (4 courses of CS, n ¼ 33), arm C (2 courses of DCS, n ¼ 33), and arm D (4 courses of DCS, n ¼ 33). A flow diagram of the patients is provided in Figure 1 . Table 1 shows the patient demographics and tumor characteristics. The actual courses were defined as one course when cisplatin (CDDP) was provided at least one time during one course. Table 2 shows the pathological response of the primary tumor. The rate of pathological response, defined as a complete response or less than 10% of the residual cancer remaining, was 19.4% (6 of 31) in arm A, 19.4% (6 of 31) in arm B, 12.1% (4 of 33) in arm C and 18.8% (6 of 32) in arm D, and was 19.4% in the CS group and 15.4% in the DCS group and 15.6% in the 2-course group and 19.0% in the 4-course group. The pathological complete response rate was 12.9% (4 of 31) in arm A, 9.7% (3 of 31) in arm B, 6.1% (2 of 33) in arm C and 6.3% (2 of 32) in arm D. The pathological complete response rate was 11.3% (7 of 62) in the CS arm and 6.2% (4 of 65) in the DCS arm, and 9.4% (6 of 64) in the patients treated with 2 courses and 7.9% (5 of 63) in those treated with 4 courses. Supplementary Table S1, available at Annals of Oncology online, shows the pathological response rate stratified by the histological type. The pathological response rate of the DCS arm was lower than that of the CS arm in both the intestinal and diffuse types.
Response
Chemotherapy-related toxicities
Supplementary Table S2, available at Annals of Oncology online, shows the details of chemotherapy related-toxicities. The most frequently detected toxicities (all grades) in the CS arm were anemia in 57 patients (91.9%), followed by neutropenia in 47 (75.8%) and anorexia in 41 (66.1%), while those in the DCS arm were anemia in 62 patients (95.4%), followed by neutropenia in 55 (84.6%) and leukocytopenia in 54 (83.1%). The respective major grade 3 or 4 hematological toxicities (CS/DCS) were leukocytopenia (14.1%/26.2%), neutropenia (29.7%/47.7%), anemia (14.1%/12.3%) and platelet reduction (3.1%/1.5%). Febrile neutropenia was observed in 6.3% of CS and 4.6% of DCS. The respective major nonhematological toxicities (CS/DCS) were appetite loss (64.1%/76.9%), fatigue (42.2%/47.7%), nausea (31.3%/49.2%), diarrhea (28.1%/40.0%), mucositis (14.1%/ 32.3%) and vomiting (12.5%/18.5%).
Surgery
Supplementary Table S3, available at Annals of Oncology online, shows the details of the surgical procedure carried out. Most patients received total gastrectomy and D2 dissection. More than half of the patients who received D2 total gastrectomy underwent splenectomy. The surgical morbidities (all grade) are shown in supplementary Table S4 , available at Annals of Oncology online. Grade 3 morbidities included anastomotic leakage, which occurred in 3% of the patients in arm A; pancreatic fistula, which occurred in 6% of the patients in arm C and 3% of the patients in arms B and D; and abdominal abscess, which occurred in 3% of the patients in arms A and C. Readmission was observed in two patients (one each from arms C and D). None of the patients required reoperation. No surgical mortalities were observed.
Discussion
The present randomized phase II study aimed to select the CS doublet regimen or the DCS triplet regimen including docetaxel as well as two or four courses of NAC as a test arm in future phase III study for resectable locally advanced gastric cancer. The major findings of this study were that the rate of pathological response was not increased by adding docetaxel to the CS regimen or by additional two courses of chemotherapy. Our results do not support three-drug therapy with a taxane over two-drug therapy or any more treatment beyond two cycles as an attractive candidate for the test arm of NAC.
Recently, the FLOT4-AIO trial suggested a higher pathologic response rate in the taxane-containing arm than in taxane-absent arm. The trial showed that the pathological complete and subtotal regression was higher in the docetaxel/oxaliplatin/leucovorin/fluorouracil (FLOT) group than in the epirubicin/cisplatin/fluorouracil or capecitabine (ECF/ECX) group [21] . In the present study, the pathological response was not increased by adding docetaxel to the CS regimen. According to the FLOT4-AIO study, the pathological response rate was increased by adding docetaxel in the intestinal type but not in the diffuse type. In the present study, the pathological response rate was not improved by adding docetaxel to the CS regimen in either the intestinal or diffuse types. On comparing the findings of FLOT4-AIO and the present study, the dose-intensity ( Decreasing the S-1 dose intensity in the DCS regimen might offset the effect of adding taxane in the present study. However, no benefits of adding taxane were observed in two phase III studies of postoperative adjuvant chemotherapy [22, 23] . The ITACA-S study failed to detect any improvement in the DFS or OS by the sequential treatment of FOLFIRI followed by docetaxel plus cisplatin compared with 5-FU/LV. The SAMIT study also observed no survival benefit by fluoropyrimidine followed by paclitaxel against fluoropyrimidine alone. Thus, the DI of fluoropyrimidine and the sequential or concurrent use of taxane may be key factors affecting the improvement of the response or survival.
Recent trials from the UK and the USA have suggested that increasing the number of chemotherapy cycles leads to a higher pathologic response rate. The UK Medical Research Council randomized OEO5 trial found that the rate of complete and subtotal regression was higher with four courses of epirubicin/cisplatin/capecitabine than with two courses of cisplatin/5 fluorouracil [24] . Another phase II trial from the US similarly showed that additional induction chemotherapy to chemoradiation tended to increase the rate of pathologic complete response [25] . In the present study, however, the increase in the pathological response by an additional two courses of therapy was limited. The findings from these two previous studies and our present study suggest that whether or not additional chemotherapy increases the pathological response depends on the chemotherapy regimen and strategy.
In the present study, the severity of adverse events was slightly greater with DCS than with CS. However, stopping therapy due to adverse events was found in 12 patients (19.4%) in the CS arm and 5 patients (7.7%) in the DCS arm, while that due to disease progression was observed in 2 patients (3.2%) in the CS arm and 2 patients (3.1%) in the DCS arm. A lower rate of therapy termination due to adverse events was the major reason why more patients completed three-drug therapy than two-drug therapy. Different DIs of fluoropyrimidine and the schedule of CS and DCS may explain these complicated findings. The DI of S-1 was 60 mg/m 2 /week in the CS regimen and 40 mg/m 2 /week in the DCS regimen, while the DI of cisplatin was the same in both arms. Considering the schedule of S-1 administration, the patients received S-1 for 3 weeks with only a 1-week interval in the CS arm and S-1 for 2 weeks with a 2-week interval in the DCS arm. In contrast, cisplatin or taxane was administered every 4 weeks in both arms. Although DCS has slightly higher toxicity than CS, the duration for recovery was 2 weeks for DCS but only 1 week for CS. Thus, differences in the duration for recovery may have affected the continuation of chemotherapy. Furthermore, there were small differences in the PS between both arms. The rate of PS 1 was slightly higher in the CS arm than in the DCS arm (15% versus 9.2%). A short duration for recovery may be particularly hard on patients with a poor PS.
In summary, the rate of pathological response was similar between the two-and four-course DCS and CS regimens. Our results do not support three-drug therapy with a taxane over two-drug therapy or any more treatment beyond two cycles as an attractive candidate for the test arm of NAC. However, the aim of adjuvant therapy is to eradicate micrometastatic tumor cells before and/or after surgery to improve the patient's chances of survival. Whether or not the prognosis differs markedly between CS and DCS is unclear, even though the pathological response rates were similar. The long-term survival results of the present study will clarify whether or not the DCS regimen is better than the CS regimen as NAC for gastric cancer.
